Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Pharmacogenetic Response to Naltrexone For Alcohol Dependence

ClinicalTrials.gov ID: NCT00831272

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00831272. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Pharmacogenetic Response to Naltrexone for Alcohol Dependence

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aims of the study are to test for treatment outcome differences in alcohol dependent subjects randomly assigned to 12 weeks of treatment with NTX (50mg/day) or placebo among those with one or two copies of the Asp40 allele of the mu-opioid receptor compared to those homozygous for the Asn40 allele. Thus, the design of the study is a 2X2 cell double-blind randomization to NTX or placebo stratified by genotype. To meet these aims, 150 alcohol dependent outpatients with one or two copies of the Asp40 variant of the mu-opioid receptor and 190 subjects homozygous for the Asn40 variant will be recruited across the four participating sites.

Study identification

NCT ID
NCT00831272
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
David Oslin
Other
Enrollment
221 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 5, 2009 (Actual)
Primary completion
Dec 20, 2013 (Actual)
Completion
Jan 15, 2014 (Actual)
Last update posted
May 11, 2017

2009 – 2014

United States locations

U.S. sites
4
U.S. states
1
U.S. cities
3
Facility City State ZIP Site status
Geisinger Medical Center Danville Pennsylvania 17822 —
Philadelphia VA Medical Center Philadelphia Pennsylvania 19104 —
University of Pennsylvania Treatment Research Center Philadelphia Pennsylvania 19104 —
VA Pittsburgh Healthcare System Pittsburgh Pennsylvania 15206 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00831272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 11, 2017 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.